Background: Osteomyelitis is a complex and heterogeneous group of infections that require surgical and antimicrobial interventions. Because treatment failure or intolerance is common, new treatment options are needed. Daptomycin has broad Gram-positive activity, penetrates bone effectively and has bactericidal activity within biofilms. This is the first report on clinical outcomes in patients with osteomyelitis from the multicentre, retrospective, non-interventional European Cubicin w Outcomes Registry and Experience (EU-CORE SM ), a large database on real-world daptomycin use.
Introduction
Osteomyelitis is a complex and heterogeneous group of infections in which the causative pathogens are primarily Gram-positive bacteria, especially staphylococcal species. 1 The presence of a prosthetic device (and the temporal relationship to surgery) and whether bone infection is derived from a contiguous focus of infection or from haematogenous spread are crucial determinants for surgical intervention and antibiotic management strategies. Despite the use of various oral and parenteral antibiotics with clinical activity against relevant Gram-positive pathogens, treatment remains challenging and relapse rates after seemingly successful antibiotic treatment may be high. 2 -4 Specific challenges for antibiotic therapy include the inherent difficulties of tackling deep-seated infections, complications of vascular insufficiency and the involvement of biofilm-forming bacteria, including Staphylococcus aureus. Daptomycin has excellent bactericidal activity against Grampositive pathogens, including methicillin-resistant S. aureus (MRSA), 5, 6 and also retains this advantage in biofilms. 7 -9 Although it is not licensed for the treatment of osteomyelitis, it penetrates bone effectively 10 and has demonstrated efficacy in animal models of chronic MRSA osteomyelitis 11, 12 and in vitro against MRSA and coagulase-negative staphylococci isolated from patients with endocarditis or bone and joint infection, 13 with increased efficacy when used in combination with, for example, rifampicin.
14 Retrospective analyses have also indicated clinical improvement in patients with osteomyelitis treated with daptomycin. 15, 16 Additionally, the Infectious Diseases Society of America's 2011 guidelines on the management of MRSA recognize daptomycin as an option for the treatment of osteomyelitis. 17 Data from patient registries of real-world clinical experience can be helpful in providing additional information and insights, with the aim of improving outcomes in difficult-to-treat infections, including bone infections. This analysis reports a subset of data from the European Cubicin w Outcomes Registry and Experience (EU-CORE SM ), a multicentre, retrospective, noninterventional registry for the characterization of daptomycin use and associated clinical outcomes. The objectives of this analysis were to: characterize patients with osteomyelitis who received daptomycin and detail the associated pathogens; evaluate the clinical outcomes, safety and tolerability of daptomycin therapy in these patients; and describe daptomycin prescribing patterns for osteomyelitis.
Patients and methods

Patients and data collection
Investigators retrospectively enrolled patients into the EU-CORE registry who had received treatment with at least one daptomycin dose for infections caused by Gram-positive organisms and for whom all relevant information as required in the case report forms was available. All patients who received daptomycin for inpatient or outpatient treatment of osteomyelitis, with treatment initiated and completed between 19 January 2006 and 14 September 2010, were included in the analysis. Patients with peri-prosthetic joint infections were eligible for inclusion in this analysis, whereas patients with septic arthritis were excluded. Patients were considered to have permanent prosthetic device-related osteomyelitis if infection was associated with a prosthetic joint or temporary prosthetic device-related osteomyelitis if infection was associated with a spacer. Full data collection methods have been described previously. 18 Written informed consent that complied with the Good Clinical Practice guidelines of the International Conference on Harmonisation was obtained if required by the institutional review board or ethics committee and/or local data privacy regulations, and the protocol was approved by the health authority and the institutional review board or ethics committee, as required, in each country.
Demographic, microbiological and clinical outcome data, as well as information on antimicrobial treatment, were collected using a standardized case report form and protocol from patients at 237 institutions across Europe, Latin America, India and Russia. Of these, 77 provided data from patients with a primary diagnosis of osteomyelitis.
Definitions
Clinical outcomes at least 28 days after daptomycin therapy were assessed by investigators using protocol-defined criteria: cure was defined as resolution of clinical signs and symptoms and/or no additional antibiotic therapy necessary, or negative culture reported at the end of therapy. Improved was defined as partial resolution of clinical signs and symptoms and/or additional antibiotic therapy warranted at the end of therapy. Failure was defined as inadequate response to therapy, worsening or new/recurrent signs and symptoms, need for a change in antibiotic therapy, or positive culture reported at the end of therapy; patients for whom insufficient information was provided to allow the response to be determined were classified as non-evaluable. 18 Clinical success was used to collectively describe patients with an outcome of cure or improved. The safety and efficacy populations included all patients who received at least one dose of daptomycin; additionally, the safety population included all patients for whom any safety parameters were assessed [the statement that no adverse events (AEs) occurred was considered a valid assessment] and the efficacy population included all patients for whom clinical outcome was assessed. 18 
Results
Patient demographics and clinical characteristics
EU-CORE enrolled 3621 patients in the analysis period 2006-10 and, of these, 220 (6%) had osteomyelitis as the primary diagnosis and were included in both efficacy and safety populations ( Table 1 ). In total, 114 (52%) had non-prosthetic device-related osteomyelitis, 74 (34%) had permanent prosthetic devicerelated osteomyelitis and 32 (15%) had temporary prosthetic device-related osteomyelitis. The most common sites of primary infection were the knee and hip, which were all implant-related (peri-prosthetic infections). The population was predominantly female and elderly, with predisposing baseline conditions such as hypertension, diabetes, chronic renal or cardiac diseases, and fractures. Ten (4.6%) were receiving dialysis at initiation and at the end of treatment.
Microbiology
Daptomycin was used empirically in 105 (48%) patients, with MRSA being the suspected primary pathogen in 74/105 (70%). Culture results were obtained for 189/220 (86%) before or shortly after initiation of therapy with daptomycin. In cases for which culture results were available the most common primary pathogens were S. aureus (63/189; 33%) and coagulase-negative staphylococci (60/189; 32%).
Previous and concomitant therapy
In total, 168 (76%) patients received antibiotic therapy for osteomyelitis before receiving daptomycin (duration 1 -270 days). Glycopeptides were the most common prior treatment. Antibiotic failure was the most common reason for discontinuing prior antibiotic therapy. Of those who received prior glycopeptides, 23/73 (32%) switched because of failure and 14/73 (19%) because of intolerance. Concomitant antibiotic therapy was received by 120 (55%) patients during daptomycin treatment, most commonly fluoroquinolones (34/120; 28%) and carbapenems (24/120; 20%).
One hundred and fifteen patients (52%) underwent surgical interventions as part of their treatment (Table 2) .
Daptomycin prescribing patterns
The most frequently prescribed daptomycin dose was 6 mg/kg (123/219; 56%); 46 (21%) patients received .6 mg/kg, 15 (7%) The primary reason for stopping daptomycin was therapy completion (94 patients; 43%). Eighty-seven patients switched therapy (40%), often to oral antibiotics (69 patients; 31%). Ten (5%) discontinued because of AEs; the reason for discontinuation was recorded as 'other' for 12 (6%) and no reason was recorded for 10 (5%). Treatment failure was recorded for seven (3%) patients.
Clinical effectiveness
Clinical success was achieved in 165/220 patients [75%; 50 (23%) were categorized as cured and 115 (52%) were categorized as improved], with treatment failure observed in 19 (9%) and a non-evaluable outcome in 36 (16%; Figure 1a ). Treatment failure rates were higher in infections with permanent prosthetic devices (12%) than in infections without prostheses (8%) and infections with temporary prosthetic devices (3%). Among patients with permanent or temporary prosthetic devices, a third (36/106) had an implant removed. There was a trend to higher success rates for both types of prosthetic devices if the device was removed: immediate removal was associated with success rates of 92% (11/12 patients) for temporary devices and 88% (14/16) for permanent devices, compared with successful retention for 80% (16/20) of patients with temporary devices and 71% (41/58) of patients with permanent devices.
Treatment outcomes by primary infecting pathogen are summarized in Figure 1(b) . The lowest treatment failure rates (5%) were observed among coagulase-negative staphylococcal infections. Enterococcal infections were limited in number (11 patients), with a higher proportion of non-evaluable outcomes (27%) compared with other pathogens. Similar success was noted between patients with MRSA and methicillin-susceptible S. aureus (MSSA).
Success rates with first-line (32/50; 64%) versus second-line (133/168; 79%) daptomycin treatment were similar. Similarly, no clear trends related to daptomycin dose were apparent: clinical success was observed in 34/44 (77%) who received ≥4 to ≤5 mg/kg daptomycin, 96/130 (74%) who received .5 to ≤6.2 mg/kg, 23/28 (82%) who received .6.2 to ,8 mg/kg and 11/17 (65%) who received ≥8 mg/kg daptomycin.
Safety and tolerability
All 220 patients were eligible for inclusion in the safety population. Of these, 27 (12%) had treatment-emergent AEs: 15 (7%) had treatment-related AEs and 2 (0.9%) had serious AEs considered treatment related by the investigator (renal tubular necrosis and bronchospasm). The most commonly reported treatment-related AE was malaise (three patients; 1%). Ten (5%) discontinued treatment because of an AE, regardless of relationship to daptomycin (Table 3) . Four deaths were reported; none was considered treatment-related. The primary causes of death were infections (n¼ 2) and cardiac disorders with or without renal urinary disorders (n¼ 2).
A similar proportion of patients had a creatinine clearance ,30 mL/min at the start of therapy (10%) compared with that at the end of therapy (9%). Peak serum creatine phosphokinase (CPK) concentrations were below or equal to the upper limit of normal throughout the analysis period in most patients (127/ 151; 84%) ( Figure 2 ).
Discussion
In this analysis of EU-CORE registry data, 75% of patients receiving daptomycin for osteomyelitis were assessed as clinical successes at least 28 days after treatment. This is notable for such a challenging infection type in a mostly pre-treated population who were switching to daptomycin primarily because of antibiotic treatment failure. Longer-term success rates will become available from EU-CORE with follow-up visits after 1 year and 2 years of treatment. Short-term clinical success rates of 93% and 91% have been reported in patients treated with daptomycin for osteomyelitis in the CORE w registry (US-based Cubicin w Outcomes Registry and Experience). 15, 19 Another retrospective case review reported cure in 87% of patients with osteomyelitis after completion of daptomycin given as outpatient parenteral antibiotic therapy. 16 Clinical success was higher in patients with temporary prosthetic device-related osteomyelitis than in non-prosthetic device and permanent prosthetic device-related osteomyelitis, potentially reflecting the advantage of surgical removal of the focus of infection. As prosthesis retention can only be determined as successful after a long follow-up period (in a well-selected population according to standard protocols and guidelines 20 -22 ) , the reported success rates in prosthesis retention need careful interpretation. Reasons for prosthesis retention and detail regarding debridement were not reported in the case report forms.
Patients undergoing surgery for osteomyelitis associated with an infected prosthesis caused by staphylococci were specifically 23 The optimal daptomycin dose to treat osteomyelitis has not been defined, but doses .6 mg/kg may be advantageous to compensate for low vascularization of bone tissue. 24 Initial high-dose daptomycin (10 mg/kg) is currently recommended in guidelines for treatment of several infections caused by MRSA. 17 No trend in dose-related outcomes was apparent in this analysis.
The clinical efficacy of daptomycin in osteomyelitis is supported by its pharmacokinetic and pharmacodynamic profile. Bone penetration following a single 8 mg/kg dose of daptomycin in patients undergoing joint replacement resulted in local drug levels that were greater than the susceptibility breakpoint of clinical S. aureus isolates: median daptomycin concentrations were 3.1 mg/g in bone and 22.4 mg/L in synovial fluid versus a maximum plasma concentration of 71.3 mg/L. 25 Furthermore, in patients with diabetic foot infection complicated with osteomyelitis, free concentrations of daptomycin in bone and subcutaneous adipose tissue after administration of multiple doses of 6 mg/kg were sufficient to treat MRSA and other Gram-positive bacteria. 10 The bactericidal activity advantage of daptomycin against biofilm infections compared with other antibiotics has been demonstrated consistently. 7 -9 However, because the treatment of these types of infection with monotherapy is rarely successful, the importance of using daptomycin in combination with other antibiotics has been recognized, and combination therapy with rifampicin has had high success rates in animal models of biofilm-associated MRSA infections. 14 In this analysis, 40% of patients switched therapy from daptomycin. Switch to oral therapy in osteomyelitis is an appropriate Seaton et al.
and commonly applied strategy if clinical and inflammatory marker improvement has been achieved, infection is controlled and suitable oral therapy is available. 26, 27 Oral switch is of particular relevance for patients in whom an infected prosthesis has been retained after debridement. 28 Daptomycin particularly lends itself to outpatient administration, given its 2 min daily administration time. 15, 19, 29 The data from this EU-CORE sub-analysis suggest that daptomycin is well tolerated in osteomyelitis, with a safety profile that compares favourably with previous reports, including case studies of high-dose daptomycin. 18, 30, 31 Although elevation of CPK levels is well documented with daptomycin, 32 peak CPK concentrations compared favourably with the overall EU-CORE population. 18 Here, CPK increase was reported as an AE leading to discontinuation in only one case.
This analysis is limited by the retrospective nature of the data and the relatively short follow-up period of 28 days after discontinuation of daptomycin. Long-term follow-up will help in defining the robustness of the presented results. The relatively high proportion (16%) of patients with a non-evaluable outcome in this analysis may reflect the difficulties in assessing short-term response in this complex infection and a reluctance of investigators to ascribe success of treatment after a relatively short follow-up period. It is possible that some implant-related hip and knee infections may have been misclassified as 'septic arthritis' and therefore not included in this analysis as a qualifying primary infection. This potential omission raises the possibility that the proportion of prosthesis-related osteomyelitis within EU-CORE may have been underestimated.
Although the inclusive nature of the registry is a strength, demonstrating the diversity of osteomyelitis infections treated with daptomycin in the real world, it is also a weakness with regard to assessing specific treatment responses. Various factors could not be controlled for and could have influenced treatment outcome. These factors included infection types, duration of antimicrobial therapy, surgical management strategies, and the influence of prior and concomitant antibiotic therapy. Improvements to the registry case report forms have subsequently been made to collect additional data, with longer followup, from future patients enrolling in EU-CORE.
In conclusion, this analysis suggests that daptomycin is a useful and well-tolerated treatment for osteomyelitis. The optimal dosage, regimen and value of concomitant antimicrobials and the role of surgical treatments in osteomyelitis have yet to be determined. Higher daptomycin doses, .6 mg/kg once daily, as monotherapy or in combination therapy may have potential in difficult-to-treat infections and deserve further investigation in osteomyelitis.
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